Advances in the use of biologic agents for the treatment of systemic vasculitis
- 1 January 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 21 (1), 3-9
- https://doi.org/10.1097/bor.0b013e32831d28b3
Abstract
Purpose of review Due to the well known toxicities of cyclophosphamide, substantial interest exists in finding other therapies to treat primary systemic vasculitis. Biologic agents have been proposed as an alternative to cyclophosphamide for these disorders because of their recent success in treating other rheumatic diseases. This article reviews the current state-of-the-art therapy with regards to the use of biologic agents as treatments for systemic vasculitis. Recent findings The greatest amount of experience with these agents for the treatment of systemic vasculitis is with antitumor necrosis factor agents, pooled intravenous immunoglobulin, and anti-B-cell therapies such as rituximab. Intravenous immunoglobulin is already a standard therapy for Kawasaki's disease, but should also be considered for the treatment of vasculitis associated with antineutrophil cytoplasmic antibodies when standard therapies are either ineffective or contraindicated. Early experience with tumor necrosis factor inhibitors indicates that they may be effective for the treatment of Takayasu's arteritis, but their role in the treatment of other forms of vasculitis remains controversial. Early experience with rituximab for the treatment of several forms of vasculitis has been quite promising, but must be confirmed by ongoing randomized clinical trials. Summary Biologic agents represent the next evolution in treatment for the primary systemic vasculitides. Greater understanding of these diseases has allowed us to move further away from nonspecific, highly toxic therapies toward a more directed approach. As our experience with these agents increases, they will likely form the keystone of treatment in the near future.Keywords
This publication has 59 references indexed in Scilit:
- Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-upAnnals Of The Rheumatic Diseases, 2008
- Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?Annals Of The Rheumatic Diseases, 2007
- A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effectsAnnals Of The Rheumatic Diseases, 2007
- Treatment of refractory temporal arteritis with adalimumabClinical Rheumatology, 2006
- Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosisRheumatology, 2006
- Infliximab in Takayasu arteritis: a safe alternative?Clinical Rheumatology, 2006
- Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximabJournal of Internal Medicine, 2005
- Wegener’s granulomatosis in pregnancy: A novel approach to managementAmerican Journal of Kidney Diseases, 2004
- Intravenous immunoglobulin for the treatment of Kawasaki disease in childrenCochrane Database of Systematic Reviews, 2003
- Treatment of systemic vasculitis with pooled intravenous immunoglobulinThe Lancet, 1991